Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients

Phase 1 Completed 36 enrolled Pharmacyclics LLC.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the highest dose of study drug that can be taken without causing serious side effects in patients with advanced cancer. The study will look at safety of the study drug and whether the treatment schedule is tolerated by patients.

Timeline

Start: 2007-11
Primary completion: 2010-06
Completion: 2010-09

Publications

Background Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR, Dalrymple SA. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther. 2006 May;5(5):1309-17. doi: 10.1158/1535-7163.MCT-05-0442.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abexinostat	Small molecule	30 mg/m2	Oral
Subject	Abexinostat	Small molecule	90 mg/m2	Oral

Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients

Summary

Timeline

Publications

Drugs

Indications